Beam Therapeutics Inc. Variable Lease, Cost
Beam Therapeutics Inc. (BEAM) reported Variable Lease, Cost of $6.79 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2026-02-24
- Beam Therapeutics Inc. variable lease, cost for the quarter ending 2022-12-31 was $1.05M, a 16.72% increase year-over-year.
- Beam Therapeutics Inc. variable lease, cost for the quarter ending 2022-09-30 was $643.00K, a 9.35% increase year-over-year.
- Beam Therapeutics Inc. variable lease, cost for the quarter ending 2022-06-30 was $1.53M, a 320.60% increase year-over-year.
- Beam Therapeutics Inc. variable lease, cost for the quarter ending 2022-03-31 was $1.14M, a 440.95% increase year-over-year.
- Beam Therapeutics Inc. variable lease, cost for fiscal 2025 was $6.79M, a 7.94% increase from fiscal 2024.
- Beam Therapeutics Inc. variable lease, cost for fiscal 2024 was $6.29M, a 8.97% increase from fiscal 2023.
- Beam Therapeutics Inc. variable lease, cost for fiscal 2023 was $5.78M, a 32.38% increase from fiscal 2022.
- Beam Therapeutics Inc. variable lease, cost for fiscal 2022 was $4.36M, a 111.33% increase from fiscal 2021.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2025-12-31 | $6.79M 10-K · filed 2026-02-24 | |||
| 2024-12-31 | $6.29M 10-K · filed 2026-02-24 | |||
| 2023-12-31 | $5.78M 10-K · filed 2026-02-24 | |||
| 2022-12-31 | $1.05M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-25 | $1.70M derived: sum of 2 quarters · filed 2025-02-25 | $3.23M derived: sum of 3 quarters · filed 2025-02-25 | $4.36M 10-K · filed 2025-02-25 |
| 2022-09-30 | $643.00K 10-Q · filed 2022-11-07 | $2.17M derived: sum of 2 quarters · filed 2022-11-07 | $3.31M 10-Q · filed 2022-11-07 | $4.21M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-06-30 | $1.53M 10-Q · filed 2022-08-09 | $2.67M 10-Q · filed 2022-08-09 | $3.57M derived: sum of 3 quarters · filed 2024-02-27 | $4.16M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-03-31 | $1.14M 10-Q · filed 2022-05-09 | $2.04M derived: sum of 2 quarters · filed 2024-02-27 | $2.63M derived: sum of 3 quarters · filed 2024-02-27 | $2.99M derived: sum of 4 quarters · filed 2024-02-27 |
| 2021-12-31 | $903.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.49M derived: sum of 2 quarters · filed 2024-02-27 | $1.85M derived: sum of 3 quarters · filed 2024-02-27 | $2.06M 10-K · filed 2024-02-27 |
| 2021-09-30 | $588.00K 10-Q · filed 2022-11-07 | $952.00K derived: sum of 2 quarters · filed 2022-11-07 | $1.16M 10-Q · filed 2022-11-07 | $1.30M derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-06-30 | $364.00K 10-Q · filed 2022-08-09 | $574.00K 10-Q · filed 2022-08-09 | $717.00K derived: sum of 3 quarters · filed 2023-02-28 | $966.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2021-03-31 | $210.00K 10-Q · filed 2022-05-09 | $353.00K derived: sum of 2 quarters · filed 2023-02-28 | $602.00K derived: sum of 3 quarters · filed 2023-02-28 | $851.00K derived: sum of 4 quarters · filed 2023-02-28 |
| 2020-12-31 | $143.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $392.00K derived: sum of 2 quarters · filed 2023-02-28 | $641.00K derived: sum of 3 quarters · filed 2023-02-28 | $929.00K 10-K · filed 2023-02-28 |
| 2020-09-30 | $249.00K 10-Q · filed 2021-11-08 | $498.00K derived: sum of 2 quarters · filed 2021-11-08 | $786.00K 10-Q · filed 2021-11-08 | $1.16M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $249.00K 10-Q · filed 2021-08-10 | $537.00K 10-Q · filed 2021-08-10 | $909.00K derived: sum of 3 quarters · filed 2022-02-28 | $1.05M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $288.00K 10-Q · filed 2021-05-11 | $660.00K derived: sum of 2 quarters · filed 2022-02-28 | $800.00K derived: sum of 3 quarters · filed 2022-02-28 | $940.00K derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $372.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $512.00K derived: sum of 2 quarters · filed 2022-02-28 | $652.00K derived: sum of 3 quarters · filed 2022-02-28 | $811.00K 10-K · filed 2022-02-28 |
| 2019-09-30 | $140.00K 10-Q · filed 2020-11-10 | $280.00K derived: sum of 2 quarters · filed 2020-11-10 | $439.00K 10-Q · filed 2020-11-10 | |
| 2019-06-30 | $140.00K 10-Q · filed 2020-08-12 | $299.00K 10-Q · filed 2020-08-12 | ||
| 2019-03-31 | $159.00K 10-Q · filed 2020-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |